Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • Subscribe Now
      • My Subscription
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » Dual Antiplatelet Therapy Results in Increase in Serious Hemorrhages Following TIA or Minor Stroke
    STROKE ALERT

    Dual Antiplatelet Therapy Results in Increase in Serious Hemorrhages Following TIA or Minor Stroke

    December 1, 2019
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share

    Related Articles

    Dual Antiplatelet Therapy Increases Serious Hemorrhages Following TIA or Minor Stroke

    Dual Antiplatelet Therapy for Minor Ischemic Stroke or TIA

    Dual Antiplatelet Therapy for Acute Ischemic Stroke and TIA

    Related Products

    Optimal Antiplatelet Therapy for Secondary Prevention of Ischemic Stroke

    Intracerebral Hemorrhages Associated with Non-vitamin K Oral Anticoagulants Appear to Be Smaller than Those Associated with Warfarin

    Every 5-minute Delay in Performing Endovascular Reperfusion Results in 1 out of 100 Patients Having a Worse Disability Outcome

    Keywords

    stroke

    Hemorrhage

    aspirin

    clopidogrel

    By Matthew E. Fink, MD

    Louis and Gertrude Feil Professor and Chair, Department of Neurology, Associate Dean for Clinical Affairs, NYP/Weill Cornell Medical College

    Dr. Fink reports no financial relationships relevant to this field of study.

    SOURCE: Tillman H, Johnston SC, Farrant M, et al. Risk for major hemorrhages in patients receiving clopidogrel and aspirin compared with aspirin alone after transient ischemic attack or minor ischemic stroke: A secondary analysis of the POINT randomized clinical trial. JAMA Neurol 2019;76:774-782.

    The POINT trial showed a 25% reduction in the composite outcome of ischemic stroke, myocardial infarction, or ischemic vascular death in patients treated with clopidogrel plus aspirin for 90 days, immediately following a transient ischemic attack (TIA) or minor acute ischemic stroke. Although there is recognition that combination therapy carries a higher risk of serious bleeding, this group of patients was thought to be at low risk for intracerebral hemorrhage because only a small area of the brain was at risk from minor ischemic syndromes. The investigators have now provided a secondary analysis reporting on the right rate and types of major hemorrhages that occurred in this cohort.

    The two groups consisted of patients treated within 12 hours of symptom onset, with either aspirin alone, 50-325 mg per day, or clopidogrel, 600 mg loading dose on day 1 followed by 75 mg daily for days 2-90. All minor and major hemorrhages were identified and recorded. The study included 269 sites worldwide that randomized 4,881 patients, at a median age of 65 years, with 45% women. Major hemorrhages occurred in 21 patients (0.9%) receiving clopidogrel plus aspirin and six patients (0.2%) in the aspirin-alone group. Four patients died from hemorrhages, three in the clopidogrel group and one in the aspirin group, and three of the four fatalities were from intracranial hemorrhage. Overall, there were seven intracranial hemorrhages, five in the clopidogrel group and two in the aspirin group. The most common location for major hemorrhages, however, was in the gastrointestinal tract.

    Overall, the risk of major hemorrhages was low in both groups, although treatment with clopidogrel and aspirin together increased the risk of major hemorrhages over aspirin alone from 0.2% to 0.9%. Caution should be taken and very close observation of patients maintained when treating with dual antiplatelet therapies.

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    Neurology Alert

    View PDF
    Neurology Alert (Vol. 39, No. 4) - December 2019
    December 1, 2019

    Table Of Contents

    Stereoelectroencephalography in Surgical Evaluation of Intractable Epilepsy

    Prognosis in Small Fiber Neuropathy

    Treating Depression in Epilepsy: To Medicate or Not?

    Patients With Stable Coronary Disease and Atrial Fibrillation Are Best Treated With Rivaroxaban, Alone

    What Is the Optimal Blood Pressure for Secondary Prevention of Stroke?

    Smartwatches for the Diagnosis of Atrial Fibrillation

    Dual Antiplatelet Therapy Results in Increase in Serious Hemorrhages Following TIA or Minor Stroke

    Begin Test

    Buy this Issue/Course

    Financial Disclosure: Neurology Alert’s Editor in Chief Matthew Fink, MD; Peer Reviewer M. Flint Beal, MD; Editorial Group Manager Leslie Coplin; Editor Jason Schneider; Executive Editor Shelly Morrow Mark; and Accreditations Manager Amy M. Johnson, MSN, RN, CPN, report no financial relationships relevant to this field of study.

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • Subscribe Now
      • My Subscription
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421

    International +1-404-262-5476

    Accounts Receivable

    1-800-370-9210
    ReliasMedia_AR@reliasmedia.com

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2020 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing